Find important updates here. DaVita is about life. We are about enriching the lives of our patients, teammates and partners, and the communities in which we operate. To know DaVita—affectionately referred to as the Village—is to understand our history and culture. From a humble start to striving to become a pioneer in health care around the world, see how DaVita has progressed through the years. March New CEO Kent Thiry and others take over leadership duties and work to transform the company and unite its workforce through a mission-and values-based approach.
Chronic kidney failure, technically known as end-stage renal disease ESRD , was treatable in three ways. A kidney transplant offered the only cure for ESRD; without a successful transplant, the disease was irreversible and ultimately fatal.
A shortage of kidney donors severely limited the number of transplants, however. Only 5 percent of ESRD patients in the United States could hope for a transplant, leaving dialysis--the removal of waste and toxins from the blood--as the only treatment option for a vast majority of ESRD patients. With dialysis, there were two treatment options: peritoneal dialysis and hemodialysis.
Peritoneal dialysis usually was performed in the patient's home, while hemodialysis, the most common form of ESRD treatment, typically was performed in a hospital or an outpatient facility. Of those on dialysis in the United States, an estimated 92 percent received hemodialysis, a treatment that used a dialyzer to remove toxins, fluid, and chemicals from the patient's blood and another device that controlled external blood flow and monitored the patient's vital signs.
Hemodialysis typically was administered three times a week to an individual patient. In macabre terms, providing service to ESRD patients represented a growth industry. Specifically, the number of patients requiring chronic dialysis services in the United States increased at a 9 percent compounded annual rate during DaVita's first decades in business, jumping from 66, in to , in By , there were , individuals in the nation who required DaVita's services.
Aside from the escalating need for dialysis treatment, DaVita, from a business standpoint, was aided by another trend. Historically, outpatient dialysis facilities composed a loosely-knit, fragmented industry, with ownership of the centers held by groups of nephrologists or by hospitals.
During the s and s, however, a new breed of operators began to emerge: multi-center dialysis companies with national, if not global, aspirations of market domination.
During the s in particular, the industry began to consolidate, as companies of DaVita's ilk became more prominent within the dialysis services industry. For example, seven major multi-facility dialysis providers owned 45 percent of the 3, facilities in operation in , a sharp increase from the 30 percent they operated four years earlier. During this same four-year period, the number of facilities owned by independent physicians declined from 37 percent to 27 percent as physicians--nephrologists, generally--sought relief from adhering to changing government regulations and administrative burdens.
Hospitals, too, were bowing out of providing dialysis services, choosing, like much of corporate America, to outsource the management of their facilities. In , 33 percent of dialysis facilities were based in hospitals. In , 28 percent of the country's facilities fell under the purview of hospitals. The two trends of the dialysis industry--growth in the number of ESRD patients in the United States and the consolidation of facility ownership--worked in DaVita's favor, serving as the impetus for its creation and, ironically, nearly causing its ruin.
We make a difference. We feel rewarded — personally and as a team — because what we do in our jobs is consistent with our goals and dreams. We enjoy what we do. We know kidney dialysis is hard work; but even hard work can be fun.
We take our jobs seriously, but we feel a fun environment delivers better care to our patients while creating a better work environment for our teammates. We strive for excellence and we have fun. Baxter International, Inc. It was founded in w Celesio AG history, profile and corporate video Celesio AG is a Germany-based pharmaceutical distribution holding company. The Company, which is active in 27 countries, operates through three business divisions: Pati Public support from individuals, businesses and foundations account for the remaining 45 percent of revenue.
Toggle navigation. Program Calendar. Apply as an International Mission Volunteer.
0コメント